To some extent, our current results of AM6545 are in good agreement with the effects of chronic SR141716 treatment for 6 weeks on body weight and dyslipidemia in MSG rats and diet-induced obese mice, when the impact of SR141716 on food intake was already gone, and the anti-obesity effect was totally attributed to the peripheral CB1R antagonism (Ravinet Trillou et al., 2003; Chen et al., 2013). Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.